Navigation Links
Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
Date:12/9/2009

--- --- Operating activities (2,348) (1,618) Financing activities 11,597 9,659 Investing activities (245) (37) Effect of exchange rate changes on cash and cash equivalents 42 (150) --- ---- Cash and cash equivalents: Increase/(decrease) in the year 9,046 7,854 Beginning of the year 14,494 19,057 ------ ------ End of the year 23,540 26,911 ====== ======


Consolidated Balance Sheets as at
---------------------------------
(thousand $)
------------
                    31-Oct  31-Jul                          31-Oct  31-Jul
                      2009    2009                            2009    2009
                      ----    ----                            ----    ----
Current assets:                     Current liabilities:
Cash and cash
 equivalents         23,540 14,494   Accounts payable         1,984  1,299
Accounts receivable   1,178  1,053   Accrued liabilities        843    834
Inventory               867    858   Deferred lease credit       25     25
                                                                ---    ---
Prepaid and other       692  1,049                            2,852  2,158
                        ---  -----
                     26,277 17,454  Non current liabilities      90     98
                                                                ---    ---
Non current assets    2,005  1,865  Total liabilities         2,942  2,256
                                    Shareholders' equity     25,340 17,063
                      -----  -----                           ------ ------
                                    Total liabilities &
Total assets         28,282 19,319   Shareholders' Equity    28,282 19,319
                     ====== ======                           ====== ======
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
4. Helix BioPharma Corp. Announces Fiscal 2009 Results
5. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
10. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... 8, 2011   SynCardia Systems, Inc. ( www.syncardia.com ), ... Canada and CE (Europe) approved Total Artificial Heart, has ... " America,s Most Promising Companies ." The list features ... management teams, notable customers , strategic partners and ...
... Biotechnology Corporation (OTCBB: GNBT.OB) today announced that positive interim ... a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in ... 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) ... developed by its wholly-owned subsidiary, Antigen Express, Inc. ...
Cached Medicine Technology:Forbes Names SynCardia One of "America's Most Promising Companies" 2Forbes Names SynCardia One of "America's Most Promising Companies" 3Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS 2Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS 3Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS 4Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS 5
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... older Americans suffer from depression, often brought on by ... a project that followed the lives of thousands ... that Internet use among the elderly can reduce the ... "That,s a very strong effect," said Shelia Cotten, a ... media who led the project. "And it all has ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... convene for one week in Adelaide from Sunday 1 ... Medical Students Association (AMSA). ,The largest ... event brings students from each of Australias 17 medical ... week of activities. ,The Convention will feature ...
... toxicology reports have confirmed that she was drunk and had ... in Beverly Hills on Memorial Day weekend. ... the Mean Girls star had cocaine and nearly twice the ... arrested last month and cited for driving under the influence. ...
... Health Organization (WHO) has said that the risk of developing ... hours or more. ,In a research study of ... absolute risk of developing VTE, if seated and immobile for ... in 6000. ,According to the study, the two ...
... understand the mechanism by which cells grow and cancer ... Listeria Monocytogenes in their project. ,The research ... Keith Ireton, had recently found that a Listeria protein ... receptor known as Met, which has been implicated in ...
... the experts are happy about the significant improvement in ... discovery of a new virus carried by bats ... ,Health and veterinary experts have singled out Indonesia, ... bird flu contagion is particularly worrisome. ,FAO's ...
... provider in Andhra Pradesh, Thursday announced that it would ... to set up new state-of-the-art hospitals in six states. ... 10 years, plans to open new hospitals in Madhya ... ,The expansion plans were announced by eminent cardiologist and ...
Cached Medicine News:Health News:Thrombosis Risk in Travel Lasting Over Four Hours is Higher: WHO 2Health News:Study of Bacterial Pathogen may Give Insight to Cancer Development 2Health News:Avian Flu Seen in Others Birds too 2Health News:Avian Flu Seen in Others Birds too 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: